{
    "organizations": [],
    "uuid": "a71b6399211cb6d65f95abf17a990f43d37587ab",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aldeyra-therapeutics-announces-agr/brief-aldeyra-therapeutics-announces-agreement-with-johnson-johnson-innovation-to-advance-novel-immune-modulating-drugs-idUSFWN1QH116",
    "ord_in_thread": 0,
    "title": "BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 14 PM / Updated 8 minutes ago BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs Reuters Staff 1 Min Read Feb 27 (Reuters) - Aldeyra Therapeutics Inc: * ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES * ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​ * ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​ * ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​ * ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED Source text for Eikon: Further company coverage:",
    "published": "2018-02-27T15:12:00.000+02:00",
    "crawled": "2018-02-27T15:25:22.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "agreement",
        "johnson",
        "johnson",
        "innovation",
        "advance",
        "novel",
        "drug",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "aldeyra",
        "therapeutic",
        "inc",
        "aldeyra",
        "therapeutic",
        "announces",
        "agreement",
        "johnson",
        "johnson",
        "innovation",
        "advance",
        "novel",
        "drug",
        "systemic",
        "inflammatory",
        "disease",
        "aldeyra",
        "therapeutic",
        "inc",
        "entered",
        "collaborative",
        "research",
        "agreement",
        "janssen",
        "research",
        "aldeyra",
        "agreement",
        "janssen",
        "advance",
        "development",
        "existing",
        "analog",
        "reproxalap",
        "treatment",
        "systemic",
        "inflammatory",
        "aldeyra",
        "therapeutic",
        "inc",
        "collaborate",
        "janssen",
        "research",
        "activity",
        "governed",
        "joint",
        "scientific",
        "review",
        "aldeyra",
        "limited",
        "period",
        "subject",
        "condition",
        "janssen",
        "retain",
        "option",
        "negotiate",
        "exclusive",
        "license",
        "pertaining",
        "compound",
        "developed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}